Form 4: Orchestra BioMed Director Pamela Connealy Awarded Significant Equity Compensation

Orchestra BioMed Holdings, Inc. Director Pamela Ann Connealy was granted 12,422 restricted stock units and 36,797 stock options as part of her compensation.

Summary

• Pamela Ann Connealy, a Director of Orchestra BioMed Holdings, Inc. (OBIO), was awarded equity compensation on June 24, 2025.
• The compensation includes 12,422 restricted stock units (RSUs) with a price of $0 per unit.
• Each RSU represents a contingent right to receive one share of Common Stock.
• The RSUs will vest in one installment on the earlier of the one-year anniversary of the Grant Date (June 24, 2025) or the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to continuous service.
• Additionally, Ms. Connealy received 36,797 stock options with an exercise price of $3.22 per option.
• These stock options also vest in one installment on the earlier of the one-year anniversary of the Grant Date (June 24, 2025) or the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to continuous service.
• The stock options have an expiration date of June 24, 2035.
• Following these transactions, Ms. Connealy beneficially owns 33,711 shares of Common Stock directly and 36,797 derivative securities (stock options) directly.

Sentiment

Score: 6

Explanation: The sentiment is mildly positive as it reflects standard compensation practices that align director interests with shareholders, indicating stability in governance and compensation structure. It is not highly impactful on its own.

Positives

• The award of restricted stock units and stock options to a director aligns management's interests with those of shareholders, as their compensation is tied to the company's future performance.
• Equity compensation is a common practice to attract and retain experienced board members.

Future Outlook

The vesting of the awarded restricted stock units and stock options is contingent upon the Reporting Person's continuous service through the earlier of the one-year anniversary of the grant date (June 24, 2025) or the Issuer's 2026 Annual Meeting of Stockholders.

Industry Context

This Form 4 filing reports a routine equity compensation grant to a director, which is a standard practice across various industries to incentivize and align the interests of board members with company performance. It does not provide broader industry trends or competitive insights.

Stakeholder Impact

• Shareholders: The equity grant aligns the director's financial interests with shareholder value creation, potentially leading to more focused decision-making aimed at increasing stock price.
• Employees: While not directly impacting general employees, such compensation practices for leadership can set a precedent for performance-based incentives within the company.
• Director (Pamela Ann Connealy): This grant represents a significant component of her compensation, incentivizing her continued service and contribution to the company's success.

Next Steps

• The vesting of the 12,422 restricted stock units and 36,797 stock options will occur on the earlier of June 24, 2026 (one-year anniversary of grant) or the date of Orchestra BioMed's 2026 Annual Meeting of Stockholders, subject to continuous service.

Key Dates

Keywords

Orchestra BioMed Holdings, OBIO, SEC Form 4, Insider Transaction, Equity Compensation, Restricted Stock Units, Stock Options, Director Compensation, Beneficial Ownership